Uncategorized

Riboscience ESMO Presentation Highlights Safety, PK, PD and Efficacy Data From the First 19 Patients of the ENPP1 Inhibitor RBS2418 Phase 1 Study

Riboscience, LLC, announced the first presentation of data from the ongoing Phase 1 clinical trial of the ENPP1 inhibitor RBS2418 that will be delivered by Dr. Thomas U. Marron, MD, PhD, from Mount Sinai, New York at the European Society for Medical Oncology Congress 2023 on October 21, 2023.

Riboscience ESMO Presentation Highlights Safety, PK, PD and Efficacy Data From the First 19 Patients of the ENPP1 Inhibitor RBS2418 Phase 1 Study Read More »

Scroll to Top